• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Ascendis Pharma A/S

    3/24/26 4:05:07 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email
    6-K 1 d192884d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO SECTION 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of March, 2026

    Commission File Number: 001-36815

     

     

    Ascendis Pharma A/S

    (Translation of registrant’s name into English)

     

     

    Tuborg Boulevard 12

    DK-2900 Hellerup

    Denmark

    (Address of principal executive offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐

     

     
     


    INCORPORATION BY REFERENCE

    This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    Annual General Meeting Results

    On March 23, 2026, Ascendis held its Annual General Meeting. 56,234,042 ordinary shares of Ascendis (which includes 55,780,639 ordinary shares represented by American Depositary Shares), representing in total 90.16% of the ordinary shares outstanding as of the date of the Annual General Meeting, were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

    Agenda Item 1: Election of Chairman of the Meeting

    Ascendis shareholders elected Lars Lüthjohan as chairman of the meeting.

    Shareholders holding 56,172,332 ordinary shares voted in favor of the proposal.

    Shareholders holding 404 ordinary shares voted against the proposal and shareholders holding 61,306 ordinary shares abstained from voting.

    Agenda Item 3: Presentation of Audited Annual Report with Auditor’s Statement for Approval and Discharge of the Board of Directors and Management

    Ascendis shareholders adopted the audited annual report (including Sustainability and P-ESG report) for the year ended December 31, 2025 and resolved to discharge the Board of Directors (the “Board”) of the Company and management from liability.

    Shareholders holding 55,910,442 ordinary shares voted in favor of the proposal.

    Shareholders holding 238,131 ordinary shares voted against the proposal and shareholders holding 85,469 ordinary shares abstained from voting.

    Agenda Item 4: Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report

    Ascendis shareholders resolved that the consolidated loss for the year ended December 31, 2025 of EUR 228 million be carried forward to the year ending December 31, 2026 through recognition in accumulated deficit.

    Shareholders holding 56,156,016 ordinary shares voted in favor of the proposal.

    Shareholders holding 15,137 ordinary shares voted against the proposal and shareholders holding 62,889 ordinary shares abstained from voting.

    Agenda Item 5: Election of Board Members


    Ascendis shareholders re-elected all members of the Board and elected Jean-Jacques Bienaimé as a new non-executive member of the Board, with the term for each such Board member to expire at the Annual General Meeting of the Company to be held in 2027.

    Shareholders holding 48,137,709 ordinary shares voted in favor of Albert Cha. Shareholders holding 8,096,333 ordinary shares abstained from voting.

    Shareholders holding 51,152,715 ordinary shares voted in favor of Lars Holtug. Shareholders holding 5,081,327 ordinary shares abstained from voting.

    Shareholders holding 55,663,224 ordinary shares voted in favor of Jan Møller Mikkelsen. Shareholders holding 570,818 ordinary shares abstained from voting.

    Shareholders holding 50,392,308 ordinary shares voted in favor of Lisa Jane Morrison. Shareholders holding 5,841,734 ordinary shares abstained from voting.

    Shareholders holding 55,817,044 ordinary shares voted in favor of William Carl Fairey Jr. Shareholders holding 416,998 ordinary shares abstained from voting.

    Shareholders holding 50,392,563 ordinary shares voted in favor of Siham Imani. Shareholders holding 5,841,479 ordinary shares abstained from voting.

    Shareholders holding 55,564,133 ordinary shares voted in favor of Jean-Jacques Bienaimé. Shareholders holding 669,909 ordinary shares abstained from voting.

    Agenda Item 6: Election of State-authorized Public Auditor

    Ascendis shareholders re-elected Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor.

    Shareholders holding 55,573,191 ordinary shares voted in favor of the proposal.

    Shareholders holding 660,851 ordinary shares abstained from voting.

    Agenda Item 7: Proposals from the Board and/or Shareholders

    7a – Proposal from the Board of Directors

    Ascendis shareholders adopted the proposal of the Board granting authorization to the Board to purchase shares in accordance with the Danish Companies Act, Section 198 or American Depositary Shares representing a corresponding amount of shares in the Company as treasury shares.

    The Board specifically proposed the following authorization:

    “The board of directors is authorized, in accordance with the Danish Companies Act, Section 198, during the period until 22 March 2031 on one or more occasions to purchase up to nominal DKK 1,000,000 shares or American Depositary Shares representing a corresponding number of shares in the Company as treasury shares. The minimum price per share shall be DKK 1 and the maximum price per share shall not exceed the market price. The proposed authorization shall be in addition to the authorizations granted by the shareholders at the annual general meetings held in 2021 and 2023, respectively. It is noted that the authorization granted at the general meeting in 2021 will expire in May 2026.”

    Shareholders holding 55,705,278 ordinary shares voted in favor of the proposal.

    Shareholders holding 302,313 ordinary shares voted against the proposal and shareholders holding 226,451 ordinary shares abstained from voting.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Ascendis Pharma A/S
    Date: March 24, 2026     By:   /s/ Michael Wolff Jensen
          Michael Wolff Jensen
          Executive Vice President, Chief Legal Officer
    Get the next $ASND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    3/16/2026Buy
    Jefferies
    1/28/2026$342.00Overweight
    Barclays
    11/18/2025$255.00Peer Perform
    Wolfe Research
    10/17/2025$271.00Strong Buy
    Raymond James
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    More analyst ratings

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

    - Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis (SCFE) COPENHAGEN, Denmark, March 17, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; U.S. FDA-approved for pediatric and adult growth hormone defici

    3/17/26 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

    COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S., M.D., Murdoch Children's Research Institute (Australia), during ACMG 2026, the Annual Clinical Genetics Meeting held March 10-14 in Baltimore, Maryland. "Two-year data from the ApproaCH Trial demonstrated con

    3/16/26 8:00:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

    COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innova

    3/2/26 8:43:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fairey William

    3 - Ascendis Pharma A/S (0001612042) (Issuer)

    3/18/26 6:14:58 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Imani Siham

    3 - Ascendis Pharma A/S (0001612042) (Issuer)

    3/18/26 6:14:09 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Smith Scott Thomas

    3 - Ascendis Pharma A/S (0001612042) (Issuer)

    3/18/26 6:13:36 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    SEC Filings

    View All

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    3/24/26 4:05:07 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    3/17/26 4:05:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    3/16/26 4:05:07 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Ascendis Pharma

    Jefferies resumed coverage of Ascendis Pharma with a rating of Buy

    3/16/26 9:36:08 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Ascendis Pharma with a new price target

    Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00

    1/28/26 7:15:39 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Ascendis Pharma with a new price target

    Wolfe Research initiated coverage of Ascendis Pharma with a rating of Peer Perform and set a new price target of $255.00

    11/18/25 8:20:21 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

    The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growt

    2/27/26 5:57:16 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

    COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma

    2/4/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care